Genetic insights for family planning
Elevate quality of care with equitable carrier screening

Carrier screening is used to identify couples who are at risk of passing inherited disorders to their children. Traditionally, carrier screening has been offered to patients based on their ethnic background or family history. However, this approach can miss couples at risk of having a pregnancy affected by a genetic disease.

Did you know?

It takes an average of **4.8 years** to diagnose a rare genetic disease.¹

Collectively common

The total risk of serious disorders identified through carrier screening** is higher than the incidence of routinely screened for conditions.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Down syndrome</td>
<td>1 in 800</td>
</tr>
<tr>
<td>Open neural tube defects</td>
<td>1 in 1,000</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>1 in 3,500</td>
</tr>
</tbody>
</table>

Elevate quality of care by offering carrier screening to patients regardless of family history or ethnicity.

*For persons receiving Foresight Universal (176 conditions) screening. Modeled US population, excluding those with family history.

Let’s make equitable carrier screening routine practice

In 2017, the American College of Obstetrics and Gynecology (ACOG) recognized expanded carrier screening as an acceptable screening strategy.⁶

Consistency in care

Offering carrier screening routinely, regardless of family history or reported ethnicity, is the only screening approach that ensures consistent care for all patients. ACOG also acknowledges the need to streamline the screening approach to benefit more patients.

Choosing Myriad Genetics Foresight® Carrier Screen

Selecting a lab that enables you to offer carrier screening while streamlining the work associated with detecting more carriers allows you to confidently integrate carrier screening into your practice.

Panel with purpose

Have confidence in the results with the highest published at-risk couple detection for serious conditions²

Pioneer and leader

Trust in the only validated carrier screening panel in the US, backed by 20+ peer-reviewed publications and >900,000 patients screened

Complete practice support

Make it easy to integrate routine screening in your practice with the support of Myriad Complete™

Did you know?

Approximately 1 in 300 pregnancies are affected by a condition screened by the Myriad Genetics Foresight® Carrier Screen²

It takes an average of **4.8 years** to diagnose a rare genetic disease.¹

Consistency in care

Offering carrier screening routinely, regardless of family history or reported ethnicity, is the only screening approach that ensures consistent care for all patients. ACOG also acknowledges the need to streamline the screening approach to benefit more patients.

Choosing Myriad Genetics Foresight® Carrier Screen

Selecting a lab that enables you to offer carrier screening while streamlining the work associated with detecting more carriers allows you to confidently integrate carrier screening into your practice.

Panel with purpose

Have confidence in the results with the highest published at-risk couple detection for serious conditions²

Pioneer and leader

Trust in the only validated carrier screening panel in the US, backed by 20+ peer-reviewed publications and >900,000 patients screened

Complete practice support

Make it easy to integrate routine screening in your practice with the support of Myriad Complete™

Elevate quality of care by offering carrier screening to patients regardless of family history or ethnicity.

*For persons receiving Foresight Universal (176 conditions) screening. Modeled US population, excluding those with family history.
A panel with purpose: Unmatched detection of serious disorders

The Foresight® Carrier Screen detection rates

The true goal of carrier screening is to detect at-risk couples of serious diseases. That’s why we’ve designed the Foresight Carrier Screen to maximize detection rates for the diseases that matter the most.

1 in 22 couples at-risk
Leads the industry in helping providers identify couples at-risk for serious and actionable conditions.

>99% for most genes
The overwhelming majority of genes on the panel have detection rates >99%, which increases confidence in both positive and negative results.

Prioritizing clinical significance in panel design

To identify appropriate diseases for our test panel, our team of experts evaluated >650 genes based on strict criteria. Our goal is to produce not simply more, but meaningful clinical information.

The process

Severity
Is this condition only mild? Or is it serious (moderate, severe or profound)?

Actionability
Is this information helpful to patients?

Prevalence
Is the condition common enough to be of value?

Sensitivity
With the best technology available, how well can we identify carriers?

Foresight carrier screen (>170 diseases)

Using these criteria, we selected >170 diseases for the Foresight Carrier Screen that are serious, clinically-actionable, and prevalent, with maximum gene-level sensitivity.

Panel-wide deletions calling provides an additional detection rate advantage

Case example: achieving >99% cystic fibrosis (CF) detection rate

Real-time curation unlocks the true potential of full-exon sequencing

When a novel variant is detected during the sequencing process, our team of PhD scientists and genetic counselors investigate its pathogenicity, in accordance with ACMG and AMP guidelines. A combination of manual review and sophisticated software are used to ensure a thorough exploration and analysis. Only known and likely pathogenic variants are reported.

Strict disease inclusion criteria ensure that we provide meaningful clinical information to you and your patients.
Why detection rate matters:
Interpreting negative results

The higher the detection rate for a gene, the lower the risk is to have a false negative for that condition.

When one partner is a carrier, a 78% detection rate means you could miss 2 out of 10 at-risk couples.

By comparison, the Foresight Carrier Screen offers >99% detection rates for the vast majority of the genes on the panel, providing increased confidence in every result. 

Implications: Can you trust his negative result?

Targeted genotyping (97 mutations)  
Foresight® Carrier Screen

Detection rate
  78%  
  >99%

Carrier couples missed
  1 in 5  
  ~0 in 5

Additional testing to validate negative result (and increased patient anxiety)
  Trust in negative results

Myriad Complete™ makes genetic screening and testing simple for your patients and your practice

Education
Resources to help you educate your patients about genetic screening and testing

Access
Comprehensive program to make our products accessible and affordable for your patients

Results
Clear and easy-to-follow results so you can focus on care plans

Consults
Pre- and post-test education sessions with certified genetic counselors are available to help answer any questions your patients may have

She's a carrier for cystic fibrosis (Northern European descent)
His result is negative (Hispanic descent)

Resources to help you educate your patients about genetic screening and testing

Clear and easy-to-follow results so you can focus on care plans

Comprehensive program to make our products accessible and affordable for your patients

Pre- and post-test education sessions with certified genetic counselors are available to help answer any questions your patients may have

Myriad Complete™ makes genetic screening and testing simple for your patients and your practice

Raising the bar in patient care

Complete practice support